Biotechnology Buyers & Acquisitions in Florida

Tracked deals

13

13 tracked deals across 2019-2026.

Buyer mix

Strategic-led

10 strategic · 4 pe

Top trend

Volume peaked in 2023

4 tracked deals announced in 2023.

Primary Insight

What Stands Out

  • Deal structures vary: completed acquisitions, all-stock mergers, and tender offers.
  • Capability expansion is a recurring theme, including CDMO and GMP capacity, analytical services, and development/commercialization rights.
  • Florida locations are central to both targets and operating footprints (e.g., Gainesville, Tampa, Clearwater, Weston, Melbourne).
  • Repeat buyer profiles include investment managers and strategic operators, such as Syncona Limited and Medix Biochemica alongside operating-company acquirers.
  • Oncology and specialized therapeutics appear often, including gene therapy (e.g., retinal programs) and disease-area programs like Niemann-Pick Disease Type C1.

Build a buyer list for your Biotechnology deal

Find buyers actively acquiring biotechnology companies.

Find buyers like these for your deal

Buyer Snapshot

Top Buyers

Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.

Build a buyer list for your Biotechnology deal →
Buyer # Deals Focus Type
Branded Legacy, Inc. 2 OTC-listed pharmaceutical biotechnology company operating... Strategic
Arcline Investment Management 1 Growth-oriented private equity firm focused on platform i... PE
Arranta Bio 1 Contract development and manufacturing organization (CDMO... Strategic (PE-backed)
Blue Water Ventures International, Inc. 1 Publicly-listed company historically focused on shipwreck... Strategic
Clairvest Equity Partners VI (CEP VI) 1 Clairvest-managed co-investment fund (CEP VI) participati... PE
Clairvest Group Inc. 1 Toronto-based publicly listed private equity firm that ma... PE
Cyclo Therapeutics, Inc. 1 Clinical-stage biotechnology company developing Trappsol ... Strategic
Fifty 1 Labs, Inc. 1 Publicly traded (OTC) life‑sciences / biotech company pur... Strategic
Lobe Sciences Ltd. 1 North American biopharmaceutical company focused on devel... Strategic
Medix Biochemica 1 Supplier and manufacturer of critical raw materials (anti... Strategic

Acquisition Volume in Biotechnology in Florida by Year

Last 6 years

Acquisition volume by year Annual acquisition counts for the last 6 years for Biotechnology Buyers & Acquisitions in Florida. 2 2019 3 2022 4 2023 1 2024 2 2025 ~2 est. 1 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Buyer
    Telomir Pharmaceuticals, Inc.
    Target
    TELI Pharmaceuticals, Inc.
    Seller
    Certain former TELI shareholders (received milestone-based contributions and Telomir stock)
    Industry
    Biotechnology
    Type
    Buyout

    Telomir Pharmaceuticals completed its previously announced stock-for-stock acquisition of TELI Pharmaceuticals. The deal makes Telomir the sole holder of global rights to Telomir-1 (Telomir-Zn), consolidating worldwide development and commercialization under one structure.

  • Buyer
    Zephyr AI, Inc.
    Target
    Aster Insights
    Industry
    Biotechnology
    Type
    Buyout

    Zephyr AI has acquired Aster Insights, a provider of scientific and clinical intelligence for oncology discovery, making Aster a wholly owned subsidiary to deepen Zephyr's real-world evidence and oncology data capabilities. Concurrently, Zephyr appointed Dr. Allen Chao, founder of Watson Pharmaceuticals, as CEO to lead the combined company's expansion of AI-driven precision medicine and clinical trial optimization.

  • Buyer
    Fifty 1 Labs, Inc.
    Target
    Genetic Networks LLC
    Industry
    Biotechnology
    Type
    Buyout

    Fifty 1 Labs, Inc. (OTC: FITY) has acquired Genetic Networks LLC in a transaction announced March 2025; several press releases indicate the deal was structured as a stock consideration (one report cites a $10 million stock deal). 4Cable TV International, Inc. (OTC: CATV) facilitated the transaction as part of its reverse-merger preparations and announced a related dividend for CATV shareholders; Fifty 1 Labs said the acquisition positions it to pursue expanded biotech capabilities and potential multi-million-dollar DoD contracts.

  • Buyer
    Branded Legacy, Inc.
    Target
    All In Extracts LLC
    Industry
    Biotechnology
    Type
    Buyout

    Branded Legacy, Inc. (OTC.PK: BLEG), a Melbourne, Florida–based pharmaceutical biotechnology company, has completed the acquisition of All In Extracts LLC, a Tampa, Florida–based medicinal ethnobotany and botanical extracts manufacturer. The deal adds proprietary delivery systems, lab and cultivation capacity (including 800 sq ft of lab space and 16 acres of grow space) to Branded Legacy’s subsidiaries and supports product and capability expansion into supplements and related health-and-wellness markets.

  • Buyer
    Cyclo Therapeutics, Inc.
    Target
    Applied Molecular Transport Inc.
    Seller
    Applied Molecular Transport stockholders
    Industry
    Biotechnology
    Type
    Buyout

    Cyclo Therapeutics completed an all-stock merger with Applied Molecular Transport (AMT), with AMT shareholders receiving 0.1331 shares of Cyclo Therapeutics for each AMT share (approximately 5,822,720 Cyclo shares, or ~18% of the combined company). The combined, Nasdaq-listed company will operate as Cyclo Therapeutics, focus on advancing the Phase 3 TransportNPC study of Trappsol Cyclo for Niemann-Pick Disease Type C1, be led by Cyclo's existing management and headquartered in Gainesville, Florida.

  • Buyer
    Branded Legacy, Inc. (BLEG)
    Target
    MariJ Pharmaceuticals, Inc.
    Seller
    Rick Pertile (CEO of MariJ Pharmaceuticals, Inc.)
    Industry
    Biotechnology
    Type
    Buyout

    Branded Legacy, Inc. (OTC: BLEG) completed the acquisition of MariJ Pharmaceuticals, Inc., a Clearwater, Florida-based certified-organic CBD extraction and production company, on December 4, 2023. The deal transfers MariJ's mobile CO2 extraction units, licensed vehicles, production lab, IP (including a patent), organic certifications, customer and operational databases, and licenses to Branded Legacy in exchange for preferred series stock and cash.

  • Buyer
    Lobe Sciences Ltd.
    Target
    Altemia & Company, LLC
    Seller
    Altemia & Company, LLC, Altemia members (Selling Members)
    Industry
    Biotechnology
    Type
    Buyout

    Lobe Sciences Ltd. signed an amendment to its share purchase agreement to acquire a 100% interest in Altemia & Company, LLC, including assets, know‑how, IP and commercial inventory related to Altemia, a medical food for sickle cell disease. The amended terms provide for the return and milestone-based reissuance of 76,000,000 Lobe common shares to the Altemia selling members upon achievement of specified development, delivery, commercial sale and tech-transfer milestones.

  • Buyer
    Clairvest Group Inc., Clairvest Equity Partners VI (CEP VI)
    Target
    Boca Biolistics
    Industry
    Biotechnology

    Clairvest Group Inc., together with its Clairvest Equity Partners VI co-investment pool, made a US$25 million equity investment in Boca Biolistics, partnering with management (founders Valentin Adia and Michael Morris) who rolled a meaningful portion of their equity. Boca Biolistics is a clinical research organization and biobanking/biomaterials company that procures, stores and sells human biospecimens and also provides in-house analytical laboratory services; the capital will support the company’s next phase of growth and capability expansion.

  • Buyer
    Syncona Limited
    Target
    Applied Genetic Technologies Corporation
    Industry
    Biotechnology
    Type
    Buyout

    Syncona Limited will acquire Applied Genetic Technologies Corporation (AGTC) via a tender offer, paying $0.34 per share in cash upfront (approximately $23.5 million) with contingent value rights (CVRs) that could provide up to an additional $0.73 per share (up to $50.0 million) for total potential consideration of up to $1.07 per share. The transaction, unanimously approved by AGTC’s board, will take AGTC private and is intended to advance AGTC's retinal gene therapy programs amid funding challenges for the public company.

  • Buyer
    Medix Biochemica
    Target
    Bioresource Technology (BRT)
    Industry
    Biotechnology
    Type
    Buyout

    Medix Biochemica has acquired a 100% stake in US-based Bioresource Technology (BRT) to expand its base matrix capabilities and strengthen its presence in the United States. BRT will be integrated into Medix Biochemica’s IVD Biomaterials Business Unit (St. Louis) while operations continue in Weston, Florida, and BRT leadership will serve as strategic advisors.

  • Buyer
    Blue Water Ventures International, Inc.
    Target
    Psycheceutical, Inc.
    Industry
    Biotechnology
    Type
    Buyout

    Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.

  • November 13, 2019
    Buyer
    Arranta Bio
    Target
    Captozyme
    Industry
    Biotechnology
    Type
    Addon

    Arranta Bio has acquired Captozyme and integrated its Gainesville, Florida team and facilities to create a Center of Excellence for microbiome process and analytical development and early clinical supply. The acquisition expands Arranta's CDMO capabilities for live biotherapeutics and transfers Captozyme's clinical GMP capacity while Captozyme's enzyme therapeutic assets were spun out into Oxidien Pharmaceuticals.

  • Buyer
    Arcline Investment Management
    Target
    Akron Biotechnology LLC
    Industry
    Biotechnology
    Type
    Buyout

    Arcline Investment Management has acquired a majority interest in Akron Biotechnology LLC, a supplier of cGMP-compliant materials and services for cell and gene therapy manufacturers. Akron will remain led by founder and CEO Dr. Claudia Zylberberg, and Arcline plans to expand Akron's manufacturing capacity and pursue complementary acquisitions to build a platform in regenerative medicine.

Build a buyer list for your Biotechnology deal

Find buyers actively acquiring biotechnology companies.

Apply as a Buyer

Frequently Asked Questions

What kinds of biotechnology acquisitions are represented in Florida deals from 2019–2026?

The page includes completed acquisitions and mergers/tender-offer transactions (including an all-stock merger and a cash tender offer with CVRs), with outcomes focused on consolidating rights or expanding research, clinical, and operational capabilities.

Which Florida cities show up frequently in these biotech transactions?

Several deals reference Florida operating footprints and/or headquarters in locations including Gainesville, Tampa, Clearwater, Weston, and Melbourne.

What capability areas do acquirers most often target in Florida biotechnology?

Common themes include expanding development and commercialization rights, strengthening CDMO/analytical or GMP capacity, and adding data/clinical intelligence or specialized production and delivery capabilities.

Do the listed deals include both strategic buyers and investors?

Yes. Transactions involve strategic operators and investors/investment managers, including Syncona Limited, Medix Biochemica, and Clairvest Group Inc. as part of equity investment activities.

Related Acquisition Pages